Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) diagnoses are frequently missed or delayed and standard treatments - ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Background: Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more ...

Albert Fiori was diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy or CIDP, a rare autoimmune disease that affects his eye, one arm and one leg. But he is not letting that stop him from ...

Polyneuropathy occurs when multiple peripheral nerves become damaged. Symptoms include problems with sensation, coordination, or other body functions. Polyneuropathy is also known as peripheral ...

Inflammatory disorders often cause myelin damage, but there are other causes. When you think of myelin, imagine the insulation around an electrical wire. Damage to myelin can make it harder for ...

BofA raised the firm’s price target on Argenx (ARGX) to $774 from $770 and keeps a Buy rating on the shares. The company pre-announced Q4 ...

(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy. VYVDURA is ...

This is a monoclonal antibody that is targeting three indications: generalized myasthenia gravis of gMG, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug t ...